ANDA 206937, held by Torrent. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 206937 (Fluoxetine Hydrochloride), held by Torrent, was first approved by FDA on Oct 21, 2016, with 4 approved supplements and 0 published complete response letters.
Fluoxetine tablets, USP are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of Premenstrual Dysphoric Disorder (PMDD) 1.1 Premenstrual Dysphoric Disorder (PMDD) Fluoxetine tablets, USP are indicated for the treatment of premenstrual dysphoric disorder (PMDD). The effectiveness of fluoxetine tablets, USP in long-term use (that is, for more than 6 months) has not been systematically evaluated in placebo-controlled trials. The use of fluoxetine tablets, USP for extended periods should be periodically re-evaluated for the individual patient.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 2016 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · tablet;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 20MG BASE · tablet;oral | Fluoxetine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 10, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 2, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 21, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters